AR090328A1 - Pirrolidina-2-carboxamidas sustituidas - Google Patents
Pirrolidina-2-carboxamidas sustituidasInfo
- Publication number
- AR090328A1 AR090328A1 ARP130100814A ARP130100814A AR090328A1 AR 090328 A1 AR090328 A1 AR 090328A1 AR P130100814 A ARP130100814 A AR P130100814A AR P130100814 A ARP130100814 A AR P130100814A AR 090328 A1 AR090328 A1 AR 090328A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- lower alkyl
- group
- cycloalkyl
- heterocycle
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- -1 nitro, ethynyl Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polyethers (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611200P | 2012-03-15 | 2012-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090328A1 true AR090328A1 (es) | 2014-11-05 |
Family
ID=47844360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100814A AR090328A1 (es) | 2012-03-15 | 2013-03-13 | Pirrolidina-2-carboxamidas sustituidas |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8993614B2 (en:Method) |
| EP (1) | EP2825528B1 (en:Method) |
| JP (1) | JP6125546B2 (en:Method) |
| KR (1) | KR20140138165A (en:Method) |
| CN (1) | CN104271554B (en:Method) |
| AR (1) | AR090328A1 (en:Method) |
| AU (1) | AU2013203662B2 (en:Method) |
| BR (1) | BR112014018959A8 (en:Method) |
| CA (1) | CA2860781A1 (en:Method) |
| CL (1) | CL2014001858A1 (en:Method) |
| CO (1) | CO6990736A2 (en:Method) |
| CR (1) | CR20140399A (en:Method) |
| DK (1) | DK2825528T3 (en:Method) |
| EA (1) | EA025557B1 (en:Method) |
| ES (1) | ES2634290T3 (en:Method) |
| HU (1) | HUE032864T2 (en:Method) |
| IL (1) | IL234173A (en:Method) |
| MX (1) | MX2014010942A (en:Method) |
| NZ (1) | NZ626505A (en:Method) |
| PE (1) | PE20142185A1 (en:Method) |
| PH (1) | PH12014501542A1 (en:Method) |
| PL (1) | PL2825528T3 (en:Method) |
| SG (1) | SG11201404344XA (en:Method) |
| SI (1) | SI2825528T1 (en:Method) |
| TW (1) | TWI586648B (en:Method) |
| UA (1) | UA113541C2 (en:Method) |
| WO (1) | WO2013135648A1 (en:Method) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013178570A1 (en) | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| CN105338959A (zh) * | 2013-06-24 | 2016-02-17 | 豪夫迈·罗氏有限公司 | 稳定的静脉内制剂 |
| BR112015031542A2 (pt) * | 2013-07-03 | 2017-07-25 | Hoffmann La Roche | métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| MX370618B (es) * | 2013-12-05 | 2019-12-17 | Hoffmann La Roche | Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma). |
| US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| EP3131878A1 (en) * | 2014-04-15 | 2017-02-22 | F. Hoffmann-La Roche AG | Solid forms of a pharmaceutically active compound |
| MX2016015255A (es) * | 2014-05-22 | 2017-06-09 | Univ Sydney | Analogos de omega-3. |
| WO2016055497A1 (en) * | 2014-10-10 | 2016-04-14 | F. Hoffmann-La Roche Ag | Methods for personalizing patient cancer therapy with an mdm2 antagonist |
| CN104496822B (zh) * | 2014-12-15 | 2016-10-26 | 扬州三友合成化工有限公司 | 一种1-氯乙基环己基丙基碳酸酯的制备方法 |
| CN115109158A (zh) | 2015-05-07 | 2022-09-27 | 阿吉纳斯公司 | 抗ox40抗体及其使用方法 |
| JP7089470B2 (ja) | 2015-12-02 | 2022-06-22 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
| CN107698598B (zh) * | 2016-08-08 | 2019-06-21 | 肖飞 | 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途 |
| WO2018027477A1 (zh) * | 2016-08-08 | 2018-02-15 | 肖飞 | 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途 |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| WO2018115051A1 (en) | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| TW201940473A (zh) * | 2017-12-20 | 2019-10-16 | 美商安捷克斯製藥公司 | 作為多激酶抑制劑的胺基碳酸鹽及尿素化合物 |
| CN114230561B (zh) * | 2020-09-09 | 2024-03-19 | 中国人民解放军海军军医大学 | 一种mdm2抑制剂类小分子化合物及用途 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| DE69120141T2 (de) | 1990-03-28 | 1996-11-28 | Shuji Kojima | Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| KR100361933B1 (ko) | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트 |
| AU1313695A (en) | 1993-12-14 | 1995-07-03 | Sandoz Ltd. | Pharmaceutical compositions containing alkyl polyoxyalkylene carboxylates |
| DE4435087A1 (de) | 1994-09-30 | 1996-04-04 | Deutsches Krebsforsch | Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen |
| ATE200030T1 (de) | 1997-01-29 | 2001-04-15 | Polymasc Pharmaceuticals Plc | Pegylationsverfahren |
| AU9402198A (en) | 1997-09-26 | 1999-04-23 | Becton Dickinson & Company | Preparing conjugates using polyethylene glycol linkers |
| US6165509A (en) | 1998-09-01 | 2000-12-26 | University Of Washington | Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| HK1054684A1 (zh) | 2000-06-08 | 2003-12-12 | La Jolla Pharmaceutical | 包含高分子量聚环氧乙烷的多价平台分子 |
| EP1405871A4 (en) | 2001-05-30 | 2004-11-17 | Mitsubishi Kagaku Iatron Inc | METHOD FOR BINDING A SUBSTANCE TO BE INCORPORATED AT A POLYMER END |
| US6939874B2 (en) * | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| US7144978B2 (en) | 2002-01-15 | 2006-12-05 | Pan Asia Bio Co., Ltd. | Multidrop tree branching functional polyethylene glycol, methods of preparing and using same |
| CA2473526C (en) | 2002-01-18 | 2013-10-22 | Biogen Idec Ma Inc. | Polyalkylene polymer compounds and uses thereof |
| US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
| JP4954864B2 (ja) | 2004-04-01 | 2012-06-20 | カーディオム ファーマ コーポレイション | イオンチャネル調節化合物のプロドラッグおよびその使用 |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| CA2584510C (en) | 2004-10-25 | 2013-05-28 | Intezyne Technologies, Incorporated | Heterobifunctional poly(ethylene glycol) and uses thereof |
| US7759383B2 (en) | 2005-02-22 | 2010-07-20 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| WO2007127473A2 (en) | 2006-04-27 | 2007-11-08 | Intezyne Technologies, Inc. | Poly (ethylene glycol) containing chemically disparate endgroups |
| WO2008109783A2 (en) | 2007-03-06 | 2008-09-12 | The Regents Of The University Of California | Detecting spin perturbations using magnetic resonance imaging |
| JP2008308690A (ja) | 2007-06-13 | 2008-12-25 | Bio-Cancer Treatment Internatl Ltd | ポリ（エチレングリコール）機能性誘導体およびその製造方法 |
| WO2009128789A1 (en) | 2008-04-17 | 2009-10-22 | Agency For Science, Technology And Research | Vesicles for intracellular drug delivery |
| US20110104074A1 (en) | 2008-06-18 | 2011-05-05 | University Of Louisville Research Foundation, Inc. | Methods for targeted cancer treatment and detection |
| BRPI0823084B1 (pt) | 2008-07-14 | 2019-07-16 | Biocon Limited | Método de síntese de uma mistura de oligômeros substancialmente monodispersa |
| US8653131B2 (en) | 2008-08-22 | 2014-02-18 | Baxter Healthcare S.A. | Polymeric benzyl carbonate-derivatives |
| ES2398342T3 (es) | 2008-09-18 | 2013-03-15 | F. Hoffmann-La Roche Ag | Pirrolidina-2-carboxamidas sustituidas |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| WO2010151269A1 (en) | 2009-06-26 | 2010-12-29 | Biotic Laboratories, Inc. | Para-xylylene based multilayer drug elution devices |
| US20110118283A1 (en) | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
| US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
| CN101991860B (zh) | 2010-11-08 | 2013-06-19 | 中国药科大学 | 泊洛沙姆-羧酸类药物偶联物及其制备方法与应用 |
| SG190230A1 (en) | 2010-11-12 | 2013-06-28 | Univ Michigan | Spiro-oxindole mdm2 antagonists |
| US8591877B2 (en) | 2011-02-02 | 2013-11-26 | Ontario Institute For Cancer Research | Cellulose-based nanoparticles for drug delivery |
| WO2012116073A2 (en) | 2011-02-23 | 2012-08-30 | The Board Of Trustees Of The University Of Illinois | Amphiphilic dendron-coils, micelles thereof and uses |
| CN102247602B (zh) | 2011-06-13 | 2013-01-02 | 中山大学 | 一种超分子水凝胶双重药物载体及其制备方法和应用 |
| AU2012301793A1 (en) | 2011-08-30 | 2014-03-20 | Quanta Biodesign, Ltd. | Branched discrette PEG constructs |
| WO2013178570A1 (en) * | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
-
2013
- 2013-03-05 US US13/785,267 patent/US8993614B2/en not_active Expired - Fee Related
- 2013-03-12 JP JP2014561405A patent/JP6125546B2/ja active Active
- 2013-03-12 AU AU2013203662A patent/AU2013203662B2/en not_active Ceased
- 2013-03-12 HU HUE13708466A patent/HUE032864T2/en unknown
- 2013-03-12 PE PE2014001419A patent/PE20142185A1/es not_active Application Discontinuation
- 2013-03-12 WO PCT/EP2013/054920 patent/WO2013135648A1/en active Application Filing
- 2013-03-12 ES ES13708466.1T patent/ES2634290T3/es active Active
- 2013-03-12 CN CN201380021271.9A patent/CN104271554B/zh not_active Expired - Fee Related
- 2013-03-12 KR KR20147025671A patent/KR20140138165A/ko not_active Withdrawn
- 2013-03-12 NZ NZ626505A patent/NZ626505A/en not_active IP Right Cessation
- 2013-03-12 SI SI201330703T patent/SI2825528T1/sl unknown
- 2013-03-12 SG SG11201404344XA patent/SG11201404344XA/en unknown
- 2013-03-12 MX MX2014010942A patent/MX2014010942A/es unknown
- 2013-03-12 CA CA2860781A patent/CA2860781A1/en not_active Abandoned
- 2013-03-12 EP EP13708466.1A patent/EP2825528B1/en not_active Not-in-force
- 2013-03-12 EA EA201491623A patent/EA025557B1/ru not_active IP Right Cessation
- 2013-03-12 DK DK13708466.1T patent/DK2825528T3/en active
- 2013-03-12 PL PL13708466T patent/PL2825528T3/pl unknown
- 2013-03-12 BR BR112014018959A patent/BR112014018959A8/pt not_active IP Right Cessation
- 2013-03-13 AR ARP130100814A patent/AR090328A1/es unknown
- 2013-03-14 TW TW102109122A patent/TWI586648B/zh not_active IP Right Cessation
- 2013-12-03 UA UAA201411036A patent/UA113541C2/uk unknown
-
2014
- 2014-06-25 CO CO14137196A patent/CO6990736A2/es active IP Right Grant
- 2014-07-03 PH PH12014501542A patent/PH12014501542A1/en unknown
- 2014-07-14 CL CL2014001858A patent/CL2014001858A1/es unknown
- 2014-08-18 IL IL234173A patent/IL234173A/en not_active IP Right Cessation
- 2014-08-26 CR CR20140399A patent/CR20140399A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090328A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| AR114159A2 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| AR121044A1 (es) | Inhibidores de egfr | |
| AR090589A1 (es) | INHIBIDORES DE b-LACTAMASA ISOXAZOL | |
| AR100137A1 (es) | Compuestos 4-amino-imidazoquinolina | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR090590A1 (es) | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA | |
| AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR093143A1 (es) | Compuestos de 2-aminopiridina | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| AR092684A1 (es) | Compuestos de sulfonamida sustituidos | |
| AR085203A1 (es) | Inhibidores benzimidazol del virus sincitial respiratorio | |
| AR093937A1 (es) | Compuestos quimicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |